BioSpace News Archive

Avantor, Inc. today announced the creation of a new Scientific Advisory Board (SAB), which will provide strategic guidance and consult on the Company’s mid- to long-term research and development efforts to deliver solutions for the life sciences industry, including biotech and pharma customers.

Meitheal Pharmaceuticals, Inc. announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. (THDB) to commercialize three insulin biosimilars — insulin aspart, insulin lispro, and insulin glargine — in the U.S.

Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying AI and machine learning.

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO).

ProSomnus, Inc. announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC.

Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.

The Brain Aneurysm Foundation, the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, from 12:25 to 12:55 p.m. ET.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation designation for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain Amyloidosis.

Seelos intends to use the net proceeds from the offering for general corporate purposes, to advance the development of its product candidates and the repayment approximately $0.7 million under the convertible promissory note previously issued to Lind Global Asset Management V, LLC.